AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2404433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 39233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 100 mg Betadrenol daily for three days
Number of subjects: 29
Study 39233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 100 mg Betadrenol daily for ten days
Number of subjects: 29
Study 39233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31910822 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme laryngeal mask airway (SLMA) insertion
Number of subjects: 45
Study 31910822 — intervention group
Group type: COMPARATOR
Intervention: ProSeal laryngeal mask airway (PLMA) insertion
Number of subjects: 45
Study 30954304 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin plus ciclosporin
Number of subjects: 0
Study 30954304 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin
Number of subjects: 0
Study 28202770 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (5 mg/kg for 12-17 years, 7 mg/kg for 7-11 years, 9 mg/kg for 2-6 years, 10 mg/kg for 12-23 months)
Number of subjects: 389
Study 28202770 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatment (primarily clindamycin or vancomycin)
Number of subjects: 389
Study 28202770 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 389
Study 28202770 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatment
Number of subjects: 389
Study 25611207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg daily for 1 week)
Number of subjects: 0
Study 22886783 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CRP (≥2 mg/L)
Number of subjects: 2153
Study 22886783 — intervention group
Group type: COMPARATOR
Intervention: No elevated CRP (<2 mg/L)
Number of subjects: 2153
Study 21147190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedonic cues (association with yoghurt liking)
Number of subjects: 39
Study 21147190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory cues (association with sweetness or saltiness)
Number of subjects: 39
Study 21147190 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal cue presentations
Number of subjects: 39
Study 21147190 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraliminal cue presentations
Number of subjects: 39
Study 19440073 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement (200 mg of testosterone cypionate intramuscular injections every 10 days)
Number of subjects: 23
Study 19440073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 19440073 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement
Number of subjects: 23
Study 16750472 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 0
Study 16750472 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine after inadequate PFMT
Number of subjects: 0
Study 16750472 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine alone
Number of subjects: 0
Study 16750472 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 15823769 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (400 mg/d)
Number of subjects: 37
Study 11578887 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron (Group O)
Number of subjects: 164
Study 11578887 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (Group M)
Number of subjects: 164
Study 11578887 — intervention group
Group type: COMPARATOR
Intervention: 10 mL normal saline (Group P)
Number of subjects: 164
Study 11578887 — intervention group
Group type: EXPERIMENTAL
Intervention: Group O and Group M
Number of subjects: 164
Study 15102384 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 100
Study 15102384 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 100
Study 7930025 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at concentrations of 100-2000 ppb
Number of subjects: 6
Study 3797170 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature controlled at 35.5 degrees C
Number of subjects: 18
Study 3797170 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature controlled at 36.5 degrees C
Number of subjects: 18
Study 3797170 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature controlled at 37.5 degrees C
Number of subjects: 18
Study 3797170 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal abdominal skin temperature control
Number of subjects: 18
Study 30704522 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted parathyroid glands at novel sites (group B)
Number of subjects: 280
Study 30704522 — intervention group
Group type: COMPARATOR
Intervention: Transplanted parathyroid glands at traditional sites (group A)
Number of subjects: 280
Study 30704522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 280
Study 27916406 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI (symptomatic participants)
Number of subjects: 53
Study 27916406 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI (asymptomatic participants)
Number of subjects: 53
Study 27916406 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 53
Study 26008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) alone
Number of subjects: 189
Study 26008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) in combination with valproic acid (VPA)
Number of subjects: 189
Study 26008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) in combination with all-trans retinoic acid (ATRA)
Number of subjects: 189
Study 26008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (DAC) in combination with both VPA and ATRA
Number of subjects: 189
Study 23530110 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CVP
Number of subjects: 534
Study 23530110 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 534
Study 23530110 — intervention group
Group type: EXPERIMENTAL
Intervention: R-FM
Number of subjects: 534
Study 21270189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 491
Study 21270189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 491
Study 21270189 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (45 mg)
Number of subjects: 491
Study 19789970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI)
Number of subjects: 1000
Study 19789970 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic and direct current cardioversion (A+DCCV)
Number of subjects: 1000
Study 19789970 — intervention group
Group type: COMPARATOR
Intervention: Atrioventricular junctional ablation (AVJA)
Number of subjects: 1000
Study 16839321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 367
Study 15545541 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pass CO(2) laser skin resurfacing with cold-air cooling
Number of subjects: 8
Study 11411653 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine (Nicorette® chewing gum)
Number of subjects: 25
Study 9121968 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 30
Study 9121968 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 30
Study 7911147 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefoxitin
Number of subjects: 250
Study 7911147 — intervention group
Group type: COMPARATOR
Intervention: 2 g piperacillin
Number of subjects: 250
Study 3661948 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 24
Study 3661948 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study 3661948 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 24
Study 3661948 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 24
Study 28603874 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Rest Training (LRT, 10-s rest)
Number of subjects: 14
Study 28603874 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Rest Training (SRT, 3-s rest)
Number of subjects: 14
Study 28603874 — intervention group
Group type: COMPARATOR
Intervention: Both LRT and SRT
Number of subjects: 14
Study 27827962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (5000 IU/week)
Number of subjects: 60
Study 27827962 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study 25140958 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline (400 mg once daily for 2 weeks, followed by 200 mg three times a week for 22 weeks)
Number of subjects: 160
Study 25140958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 23810627 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-oriented HIV counselling session (COC)
Number of subjects: 1607
Study 23810627 — intervention group
Group type: COMPARATOR
Intervention: Standard post-test HIV counselling
Number of subjects: 1607
Study 20529368 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment including in-home interview, self-administered questionnaire, medical/dental examination.
Number of subjects: 1152
Study 20529368 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid ultrasonography
Number of subjects: 1152
Study 20529368 — intervention group
Group type: EXPERIMENTAL
Intervention: Masticatory assessment using a colour-changeable chewing gum
Number of subjects: 1152
Study 19049379 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 17
Study 19049379 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 17
Study 12557453 — intervention group
Group type: EXPERIMENTAL
Intervention: Real contingent alpha/theta feedback training
Number of subjects: 2
Study 12557453 — intervention group
Group type: COMPARATOR
Intervention: Mock feedback control condition
Number of subjects: 2
Study 12557453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Real contingent a/t feedback and Mock feedback)
Number of subjects: 2
Study 9641689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lamifiban (1 microg/min)
Number of subjects: 2282
Study 9641689 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lamifiban (5 microg/min)
Number of subjects: 2282
Study 9641689 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lamifiban and heparin
Number of subjects: 2282
Study 9641689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lamifiban and heparin
Number of subjects: 2282
Study 9641689 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (placebo and heparin)
Number of subjects: 2282
Study 7979888 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (cognitive-behavioral relapse prevention)
Number of subjects: 121
Study 7979888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (desipramine hydrochloride)
Number of subjects: 121
Study 7979888 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 121
Study 7979888 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy (supportive clinical management)
Number of subjects: 121
Study 2481743 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 36
Study 2481743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1192857 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy (10 percent of blood volume)
Number of subjects: 18
Study 1192857 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 18
Study 1192857 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 18
Study 1192857 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy and Control
Number of subjects: 18
Study 30476451 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS-generated report cards
Number of subjects: 108
Study 30476451 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time CDS alerts
Number of subjects: 108
Study 30476451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both feedback types (report cards and alerts)
Number of subjects: 108
Study 30476451 — intervention group
Group type: COMPARATOR
Intervention: No feedback (baseline)
Number of subjects: 108
Study 28851188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg orally before PCI and 15 mg/d for 3 days)
Number of subjects: 120
Study 25389256 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg
Number of subjects: 118
Study 25389256 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/ritonavir 800/100 mg
Number of subjects: 118
Study 23724021 — intervention group
Group type: EXPERIMENTAL
Intervention: BKSE1.0
Number of subjects: 138
Study 23724021 — intervention group
Group type: EXPERIMENTAL
Intervention: BKSE0.5
Number of subjects: 138
Study 23724021 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 138
Study 21612894 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg/day amikacin
Number of subjects: 99
Study 21612894 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg/day amikacin
Number of subjects: 99
Study 21612894 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/kg/day (historical standard dose)
Number of subjects: 99
Study 18848318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate) 0.05% eye drops, four times daily
Number of subjects: 150
Study 18848318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A 0.05% eye drops, twice daily
Number of subjects: 150
Study 18848318 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with preservative-free artificial tears alone
Number of subjects: 150
Study 16817814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (0.15 mg/kg)
Number of subjects: 0
Study 16817814 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosterone (0.15 mg/kg)
Number of subjects: 0
Study 16817814 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosterone (0.04 mg/kg)
Number of subjects: 0
Study 16817814 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 15489467 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet changes (percent change in percentage kilocalories from carbohydrate)
Number of subjects: 127
Study 15489467 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet changes (percent change in fruit/100% juice)
Number of subjects: 127
Study 15489467 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity changes (percent change in minutes of moderate‐to‐vigorous activity)
Number of subjects: 127
Study 15489467 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐to‐vigorous physical activity
Number of subjects: 127
Study 11313301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclosporine, 4 mg x kg(‐1) x day(‐1)
Number of subjects: 30
Study 11313301 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone, 40 mg/day
Number of subjects: 30
Study 9257745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 99
Study 9257745 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus Gentamicin (P+G)
Number of subjects: 99
Study 8292833 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional African herbal concoction (placebo)
Number of subjects: 21
Study 8292833 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial Western-style medicine (placebo)
Number of subjects: 21
Study 30986113 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop system for diabetes management
Number of subjects: 24
Study 29500567 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-CF 15 g (G1)
Number of subjects: 106
Study 29500567 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-CF 10 g (G2)
Number of subjects: 106
Study 29500567 — intervention group
Group type: COMPARATOR
Intervention: CF concealed from operator (G3)
Number of subjects: 106
Study 27396474 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-walled introducer needle
Number of subjects: 414
Study 27396474 — intervention group
Group type: COMPARATOR
Intervention: Catheter-over-needle technique
Number of subjects: 414
Study 24616420 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 24616420 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + diet/exercise
Number of subjects: 0
Study 24616420 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet/exercise alone
Number of subjects: 0
Study 21880562 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to thin ultra-fit models
Number of subjects: 138
Study 21880562 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to normal weight athletic models
Number of subjects: 138
Study 21880562 — intervention group
Group type: COMPARATOR
Intervention: Control condition (neutral objects)
Number of subjects: 138
Study 20554709 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocreatine (PCr) recovery evaluated by (31)phosphorous-MRS after submaximal exercise
Number of subjects: 121
Study 18385420 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP4A11 8590CC genotype
Number of subjects: 732
Study 16939743 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG plus corticosteroid (IVIG+PSL)
Number of subjects: 178
Study 16939743 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 178
Study 12660684 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartBar (3.3 g L-arginine, consumed twice daily for 2 weeks)
Number of subjects: 47
Study 12660684 — intervention group
Group type: COMPARATOR
Intervention: Placebo bar (consumed twice daily for 2 weeks)
Number of subjects: 47
Study 10731454 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing telephone intervention (one or two calls per week from 24th to 37th week of gestation)
Number of subjects: 1554
Study 10731454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1554
Study 9365345 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal mapping (PM) electromyography (EMG) protocol
Number of subjects: 114
Study 9365345 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal mapping (PM) combined with lower extremity (LE) EMG
Number of subjects: 114
Study 9365345 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal mapping (PM)
Number of subjects: 114
Study 1491124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg and 1,000 mg daily (administered in three divided doses)
Number of subjects: 15
Study 1491124 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (CE) 0.625 mg/day
Number of subjects: 15
Study 1491124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 4037631 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% aqueous solution of povidone-iodine (Betadine)
Number of subjects: 45
Study 4037631 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 45
Study 31394921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripple mapping (RM)
Number of subjects: 83
Study 31394921 — intervention group
Group type: COMPARATOR
Intervention: Local activation time (LAT) mapping
Number of subjects: 83
Study 31394921 — intervention group
Group type: COMPARATOR
Intervention: Local activation time (LAT) mapping after crossover to RM
Number of subjects: 83
Study 31394921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripple mapping (RM) after crossover to LAT
Number of subjects: 83
Study 29973314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime mental illness (LMI) including depression
Number of subjects: 0
Study 29973314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime mental illness (LMI) including 2+ LMIs
Number of subjects: 0
Study 29973314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime mental illness (LMI) including 2+ LMIs with depression
Number of subjects: 0
Study 29973314 — intervention group
Group type: COMPARATOR
Intervention: No history of LMI
Number of subjects: 0
Study 27307270 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D computer module (n=49)
Number of subjects: 100
Study 27307270 — intervention group
Group type: COMPARATOR
Intervention: Written text (n=51)
Number of subjects: 100
Study 23812581 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 31
Study 23812581 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision with channeled blade (KVC)
Number of subjects: 31
Study 23812581 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision with non‐channeled blade (KVNC)
Number of subjects: 31
Study 21859743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 60
Study 21859743 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 19901117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 2104
Study 19901117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense epirubicin and cyclophosphamide followed by Paclitaxel (EC/T)
Number of subjects: 2104
Study 19901117 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide followed by Paclitaxel (AC/T)
Number of subjects: 2104
Study 19901117 — intervention group
Group type: COMPARATOR
Intervention: AC/T versus CEF
Number of subjects: 2104
Study 19901117 — intervention group
Group type: COMPARATOR
Intervention: AC/T versus EC/T
Number of subjects: 2104
Study 19901117 — intervention group
Group type: EXPERIMENTAL
Intervention: EC/T versus CEF
Number of subjects: 2104
Study 19901117 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF
Number of subjects: 2104
Study 19901117 — intervention group
Group type: EXPERIMENTAL
Intervention: EC/T
Number of subjects: 2104
Study 19901117 — intervention group
Group type: COMPARATOR
Intervention: AC/T
Number of subjects: 2104
Study 19901117 — intervention group
Group type: EXPERIMENTAL
Intervention: EC/T and CEF
Number of subjects: 2104
Study 17395048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 12